Transdermal N-[N-[5-[4-(aminoiminomethly)phenyl]-1-oxopentyl]-L- -aspartyl]-L-phenylalainine or its esters and their pharmaceutically acceptable salts

The present invention is for pharmaceutical compositions for transdermal delivery of N-[N-[5-[4-(aminoiminomethyl)phenyl-1-oxopentyl]-L- -aspartyl]-L-phenylalanine or its esters and their pharmaceutically acceptable salts which are useful as platelet aggregation inhibitors. The present invention is for pharmaceutical compositions and a method of use for the transdermal delivery of N-[N-[5-[4-(aminoiminomethyl)phenyl]-1-oxopentyl]-L- -aspartyl]-L-phenylalanine or its esters and their pharmaceutically acceptable salts which are useful as platelet aggregation inhibitors.